Idorsia News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

20.12.24	Idorsia provides update on the exclusive negotiations for the global rights to aprocitentan (GlobeNewswire)
27.11.24	Idorsia enters into exclusive negotiations for global rights to aprocitentan (GlobeNewswire)
11.11.24	Idorsia is advancing the treatment of hypertension with new data at the 2024 American Heart Association (AHA) Scientific Sessions (GlobeNewswire)
29.10.24	Idorsia announces financial results for the first nine months of 2024 (GlobeNewswire)
16.10.24	New data on aprocitentan to be presented at the ASN Kidney Week 2024 (GlobeNewswire)
17.09.24	Idorsia continues to further the science of sleep and insomnia with new daridorexant data and analyses published at Sleep Europe 2024 (GlobeNewswire)
05.09.24	New data on aprocitentan to be presented at the AHA Hypertension Scientific Sessions 2024 (GlobeNewswire)
02.09.24	Amended terms of Idorsia’s 2024 convertible bonds become effective (GlobeNewswire)
25.07.24	Idorsia announces financial results for the first half 2024 (GlobeNewswire)
18.07.24	Invitation to Idorsia's Half Year 2024 Financial Reporting webcast and conference call (GlobeNewswire)
01.07.24	Idorsia’s JERAYGO (aprocitentan) approved in Europe as first and only ERA for the treatment of resistant hypertension (GlobeNewswire)
28.06.24	Higher cantonal composition authority issues written court decision in respect to the amendments to the terms of the 2024 convertible bonds (GlobeNewswire)
25.06.24	Higher cantonal composition authority approved the amendments to the terms of the 2024 convertible bonds (GlobeNewswire)
21.06.24	Idorsia’s novel treatment for chronic insomnia wins the prestigious Prix Galien Suisse 2024 innovation award in the ‘Primary & Speciality’ category (GlobeNewswire)
13.06.24	Idorsia holds its Annual General Meeting of Shareholders (GlobeNewswire)
03.06.24	New data with daridorexant to be presented at SLEEP 2024 (GlobeNewswire)
03.06.24	New data with daridorexant to be presented at SLEEP 2024 (GlobeNewswire)
31.05.24	Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024 (GlobeNewswire)
31.05.24	Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024 (GlobeNewswire)
23.05.24	Idorsia issues invitation to the 2024 Annual General Meeting of Shareholders (GlobeNewswire)
23.05.24	Idorsia issues invitation to the 2024 Annual General Meeting of Shareholders (GlobeNewswire)
21.05.24	Idorsia announces changes to Idorsia Executive Committee and Board of Directors (GlobeNewswire)
21.05.24	Idorsia announces changes to Idorsia Executive Committee and Board of Directors (GlobeNewswire)
21.05.24	Idorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigor (GlobeNewswire)
21.05.24	Idorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigor (GlobeNewswire)
21.05.24	Idorsia announces financial results for the full year of 2023 – Adapting the company to create sustainable value (GlobeNewswire)
21.05.24	Idorsia announces financial results for the full year of 2023 – Adapting the company to create sustainable value (GlobeNewswire)
14.05.24	Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call (GlobeNewswire)
14.05.24	Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call (GlobeNewswire)
06.05.24	Bondholders approve amended terms of the 2024 convertible bonds (GlobeNewswire)
06.05.24	Bondholders approve amended terms of the 2024 convertible bonds (GlobeNewswire)
01.05.24	Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond (GlobeNewswire)
01.05.24	Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond (GlobeNewswire)
26.04.24	JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension (GlobeNewswire)
26.04.24	JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension (GlobeNewswire)
23.04.24	Idorsia publishes an invitation to a bondholder meeting (GlobeNewswire)
23.04.24	Idorsia publishes an invitation to a bondholder meeting (GlobeNewswire)
17.04.24	Idorsia publishes a Financial Status required for an upcoming bondholder meeting (GlobeNewswire)
17.04.24	Idorsia publishes a Financial Status required for an upcoming bondholder meeting (GlobeNewswire)
11.04.24	Idorsia takes steps to address short-term liquidity needs (GlobeNewswire)
11.04.24	Idorsia takes steps to address short-term liquidity needs (GlobeNewswire)
22.03.24	Idorsia thanks Guy Braunstein for his years of service as he retires (GlobeNewswire)
22.03.24	Idorsia thanks Guy Braunstein for his years of service as he retires (GlobeNewswire)
20.03.24	US FDA approves Idorsia’s once-daily TRYVIO (aprocitentan) – the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with ot (GlobeNewswire)
20.03.24	US FDA approves Idorsia’s once-daily TRYVIO (aprocitentan) – the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with ot (GlobeNewswire)
18.03.24	Idorsia and Viatris successfully close the transaction for the global research and development collaboration (GlobeNewswire)
18.03.24	Idorsia and Viatris successfully close the transaction for the global research and development collaboration (GlobeNewswire)
28.02.24	Idorsia and Viatris enter into a significant global research and development collaboration (GlobeNewswire)
28.02.24	Idorsia and Viatris enter into a significant global research and development collaboration (GlobeNewswire)
10.01.24	Idorsia presents at the J.P. Morgan Healthcare Conference – Adapting Idorsia for sustainable value creation (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

27.12.24		SPI aktuell: SPI zum Ende des Freitagshandels in der Gewinnzone
27.12.24		Gewinne in Zürich: SPI am Nachmittag freundlich
27.12.24		SIX-Handel: SPI präsentiert sich am Mittag fester
27.12.24		Börse Zürich in Grün: SPI präsentiert sich zum Start des Freitagshandels fester
24.12.24		SPI-Papier Idorsia-Aktie: So viel Verlust hätte eine Investition in Idorsia von vor 3 Jahren bedeutet
23.12.24		Freundlicher Handel: SPI legt letztendlich zu
23.12.24		SPI-Handel aktuell: So steht der SPI aktuell
23.12.24		Starker Wochentag in Zürich: SPI verbucht Gewinne

27.12.24

SPI aktuell: SPI zum Ende des Freitagshandels in der Gewinnzone

27.12.24

Gewinne in Zürich: SPI am Nachmittag freundlich

27.12.24

SIX-Handel: SPI präsentiert sich am Mittag fester

27.12.24

Börse Zürich in Grün: SPI präsentiert sich zum Start des Freitagshandels fester

24.12.24

SPI-Papier Idorsia-Aktie: So viel Verlust hätte eine Investition in Idorsia von vor 3 Jahren bedeutet

23.12.24

Freundlicher Handel: SPI legt letztendlich zu

23.12.24

SPI-Handel aktuell: So steht der SPI aktuell

23.12.24

Starker Wochentag in Zürich: SPI verbucht Gewinne

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu Idorsia AG

Aktien Top/Flop

Idorsia Peer Group Nachrichten

Meistgelesene Nachrichten